Priority CommunicationsMorphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗
Introduction
Although depressive illnesses can be serious, and even lead to suicide, nearly 80 percent of people suffering from depression can be treated successfully with medication, psychotherapy, or a combination of both. Pharmacologic, biochemical and neuroanatomical studies are beginning to establish that depressive disorders are brain diseases with unique histopathological features. Profuse neurochemical research suggests that the disruption of monoaminergic neurotransmitter pathways may be critical in the pathophysiology of major depressive disorder (MDD). In particular, the serotonin and norepinephrine systems have been implicated, because nearly all clinically effective antidepressant medications affect these neurotransmitters Heninger and Charney 1987, Hollister and Claghorn 1993.
In contrast to the neurochemical literature, there are no systematic histopathological studies of neurons and glia on major depression or other mood disorders. Such studies may be highly relevant because reports in depressed patients and suicide victims reveal changes in monoamine receptors and transporters and related second messenger systems Arango et al 1995, Biver et al 1997, Klimek et al 1997, Ordway et al 1994, Pacheco et al 1996, Stockmeier et al 1998 suggesting parallel cellular changes in the cortical projection areas of monoaminergic neurons. The prefrontal cortex is a particularly good candidate for a site of cellular pathology, because this region is an important target of extensive monoamine projections originating in the brainstem nuclei including the dorsal raphe, locus coeruleus and ventral tegmental area. Evidence for histopathology of glia in the subgenual region of the prefrontal cortex in major depression was recently reported by Öngür et al. (1998).
Interest in the long overlooked morphopathology of mood disorders has recently been kindled with the emergence of in vivo brain-imaging techniques. Although the results of neuroimaging studies are sometimes conflicting, the majority of such reports have implicated the prefrontal cortex as a site of functional and structural abnormalities in mood disorders (for review see Rajkowska 1997). Inmajor depression at least two different regions, the dorsolateral prefrontal cortex (dlPFC) and the orbitofrontal-ventral region have been implicated. For example, patients with MDD consistently have reduced glucose metabolism in the left dlPFC Baxter et al 1989, Bench et al 1993, Biver et al 1994. Decreased brain metabolism was found recently in dlPFC as well as in orbitofrontal cortex (ORB) in patients with a relapse in depression induced by depletion of tryptophan (Bremner et al 1997). Abnormally decreased metabolic activity was also localized in the ventromedial subgenual region of the frontal lobe in MDD and bipolar disorder (Drevets et al 1997). In contrast, earlier studies report increased metabolism or blood flow in orbitofrontal and ventrolateral prefrontal regions in MDD patients Biver et al 1994, Buchsbaum et al 1986, Drevets and Raichle 1992, although blood flow tended to be lower in subjects with the greatest severity of depression (Drevets et al 1992). These apparent inconsistencies found in the orbitofrontal/ventral region indicate either the existence of different metabolic patterns in specific subareas of this region or imprecise anatomical localization of the observed changes.
Pathology of cortical cells may be related to the recent neuroimaging findings in patients with mood disorders. A 7% reduction of the total volume of the frontal lobe was reported in MDD (Coffey et al 1993) and substantial 39–48% decreases in the subgenual prefrontal gray matter volume were found in patients with MDD and bipolar depression (Drevets et al 1997). The specific neuronal and glial pathology underlying these gross morphological changes has not been determined to date. The present study is the first attempt to use state-of-the art morphometric methods to test whether neuronal or glial cell pathology can be identified in ORB or dlPFC regions. We also tested whether the pattern of specific cortical pathology is similar or different between prefrontal regions as suggested by the neuroimaging studies.
Section snippets
Human subjects
Human postmortem brain tissues were obtained at autopsies performed at the Cuyahoga County Coroner’s Office in Cleveland, OH. Retrospective psychiatric assessments were established at Case Western Reserve University, Cleveland, OH in accordance with Institutional Review Board policies and written consent was obtained from the next-of-kin. Dr. P.S. Goldman-Rakic (Yale University School of Medicine) generously donated additional tissues from four control brains originally obtained from the
Rostral orbitofrontal cortex (area 10–47)
Our morphometric analyses in subjects with MDD showed that the overall cortical thickness of the rORB was reduced by 12% (F[1,22] = 10.681, p = .004) as compared to normal controls (Figure 2A). These reductions in thickness were accompanied by smaller sizes of neuronal cell bodies (Figure 3). Laminar analysis of mean neuronal sizes and densities in each of the six cortical layers revealed reductions in mean neuronal size in supragranular layers (II-IIIc) of rORB in subjects with MDD (Table 2)
Cellular changes
The densities of the largest neurons were consistently reduced in the rORB, dlPFC and, to a lesser degree, in the cORB of postmortem brains from subjects diagnosed with major depressive disorder. These decreases in densities of the largest neurons in specific layers of the rORB and dlPFC were accompanied by parallel increases in the density of small neurons and were correlated with reductions in mean neuronal sizes. The latter observation suggests that neuronal shrinkage or a developmental
Conclusions
The cellular changes described here indicate that both types of brain cells, neurons and glia, are abnormal in major depression, and may contribute to pathologic changes in the prefrontal cortex related to the psychiatric disorder. The question remains whether depressed patients are genetically predisposed for the cortical cell changes found in their brains postmortem and they were born with smaller neurons or less glia or whether the cellular changes are a consequence of MDD. Alternatively,
Acknowledgements
This study was sponsored by NARSAD Young Investigators Award (GR), grants MH54710 and MH55872 (GR), The American Foundation for Suicide Prevention and MH45488 (CAS). We are grateful to G. Bissette, Ph.D. for valuable comments on the manuscript and to W. Page and M. Richmond for excellent technical assistance. We thank A. Halaris, M.D., Ph.D. for providing generous departmental support and P.S. Goldman-Rakic, Ph.D. and P. Rakic, Ph.D. for sharing software for 3-D cell counting. We acknowledge
References (50)
- et al.
Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims
Brain Res
(1995) - et al.
Frontal and parietal metabolic disturbances in unipolar depression
Biol Psychiatry
(1994) - et al.
Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-Deoxyglucose in affective illness
J Affect Disord
(1986) - et al.
Postnatal maturation of the layer III pyramidal neurons in the human prefrontal cortexa quantitative Golgi analysis
Brain Res
(1994) - et al.
Acetylcholinesterase in the human frontal associative cortex during the period of cognitive developmentearly laminar shifts and late innervation of pyramidal neurons
Neurosci Lett
(1988) - et al.
Alterations in phosphoinositide signaling and G-protein levels in depressed suicide brain
Brain Res
(1996) - et al.
Serotonin receptors in the human brain—III. Autoradiographic mapping of serotonin-1 receptors
Neuroscience
(1987) - et al.
Marked glial neuropathology in prefrontal cortex distinguishes bipolar disorder from schizophrenia
Schizophrenia Res
(1997) Diagnostic and Statistical Manual of Mental Disorders. Revised Third Edition
(1987)- et al.
Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims
Arch Gen Psychiatry
(1990)
The organization of prefrontocaudate projections and their laminar origin in the macaque monkeya retrograde study using HRP-gel
J Comp Neurol
Reduction of prefrontal cortex glucose metabolism common to three types of depression
Arch Gen Psychiatry
Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions
Psychol Med
Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex
Br J Psychiatry
Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse
Arch Gen Psychiatry
Quantitative cerebral anatomy in depression
Arch Gen Psychiatry
Subgenual prefrontal cortex abnormalities in mood disorders [see comments]
Nature
Neuroanatomical circuits in depression: implications for treatment mechanisms
Psychopharmacol Bull
A functional anatomical study of unipolar depression
J Neurosci
The cortical dopamine systemrole in memory and cognition
Adv Pharmacol
Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex
J Neurosci
Stereology of arbitrary particles: a review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson
J Microscopy
New antidepressants
Annu Rev Pharmacol Toxicol
Characterization and distribution of [125I]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain
J Pharmacol Exp Therapeut
Cited by (1284)
Progress of depression mechanism based on Omics method
2024, Journal of Pharmaceutical and Biomedical AnalysisAstrocyte-derived lactate in stress disorders
2024, Neurobiology of DiseaseStructural and biochemical alterations in dendritic spines as key mechanisms for severe mental illnesses
2024, Progress in Neuro-Psychopharmacology and Biological PsychiatryMajor depressive disorder as a neuro-immune disorder: Origin, mechanisms, and therapeutic opportunities
2023, Neuroscience and Biobehavioral Reviews
- ∗
See accompanying Editorial, in this issue.